Información para prescribir

HUMENAS® GL

REGISTRO SANITARIO:
INVIMA 2018M-0018545

PRINCIPIO ACTIVO:
Cloruro de sodio 0.9 g Vehículo c.s.p 100 ml. Excipientes: alantoína, hialuronato sódico, áloe vera, glicerina, propilenglicol, benzalconio HCl, bicarbonato sódico, c.s.

PRESENTACIÓN:
Frasco por 30 ml

HUMENAS®

REGISTRO SANITARIO:
INVIMA 2020M-0013606-R1.

PRINCIPIO ACTIVO:
Cloruro de sodio 0.65 g Vehículo c.s.p 100 ml.

UNIDAD DE VENTA:
Frasco por 30 mL.

DESLODEX® DUO

Reg. San. No. INVIMA:

INVIMA 2018M-0018531

Principio activo:

Desloratadina 5 mg y Montelukast 10 mg

Unidad de Venta:

Caja x 30 tabletas

AZEFLU®

REG. SAN. NO. INVIMA:
INVIMA 2020M-0002309-R1.

PRINCIPIO ACTIVO:
200 mcg de budesonida y 6 mcg de formoterol

UNIDAD DE VENTA:
Inhalador aerolizer y 30 cápsulas de polvo para inhalar.

OLONASE®

REGISTRO SANITARIO:
INVIMA 2018M-0018484

PRINCIPIO ACTIVO:
Olopatadina clorhidrato

PRESENTACIÓN:
 Spray nasal x 30mL

Referencias AV rinitis institucional.
  1. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology 2020;145(1):70-80.e3.
  2. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis: ICAR: Allergic Rhinitis. International Forum of Allergy & Rhinology 2018;8(2):108-352.
  3. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Current Medical Research and Opinion 2004;20(10):1549-58.
  4. Barnes ML, Ward JH, Fardon TC, Lipworth BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 2006;36(5):676-84.
  5. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. A novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. allergy asthma proc 2012;33(4):324-32.
  6. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. Journal of Allergy and Clinical Immunology 2012;129(5):1282-1289.e10.
  7. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clinical and Translational Allergy [Internet] 2018 [citado 2018 dic 10];8(1). Available from: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0210-2
  8. Data on file AZEFLU.
  9. Smith PK, Collins J. Olopatadine 0.6% Nasal Spray Protects from Vasomotor Challenge in Patients with Severe Vasomotor Rhinitis. American Journal of Rhinology & Allergy 2011;25(4):e149-52.
  10. Data on file OLONASE.
  11. Data on file Deslodex DUO.
NOVAMED S. A.
Calidad e Innovación
Más Información
Scroll al inicio